Jazz Pharmaceuticals presents Xywav data at SLEEP 2026 conference

Jazz Pharmaceuticals presented late-breaking data at the SLEEP 2026 annual meeting, detailing the real-world efficacy of Xywav. The clinical presentations focused on the drug’s impact on patients diagnosed with narcolepsy and idiopathic hypersomnia (IH), focusing on long-term safety and patient outcomes. Clinical Efficacy and Sodium Reduction Xywav, a formulation of calcium, magnesium, potassium, and sodium oxybates, is the only low-sodium oxybate approved for these sleep disorders. The data presented at the conference emphasized the importance of reducing sodium intake for patients, as narcolepsy is frequently associated with an increased risk of hypertension and cardiovascular disease. The new findings included analyses of patient transitions from high-sodium oxybate treatments to Xywav. Researchers reported that the low-sodium alternative maintained efficacy in managing excessive daytime sleepiness and cataplexy while providing a more favorable cardiovascular profile for chronic use. Addressing Idiopathic Hypersomnia The presentations also highlighted the drug's performance in treating idiopathic hypersomnia, a condition characterized by uncontrollable sleepiness despite…